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ABBREVIATIONS 
 
APTT   Activated Partial Thromboplastin Time 
ASV   Anti Snake Venom 
Bl. Urea   Blood Urea 
CKD   Chronic Kidney Disease 
eGFR   Estimated glomerular filtration rate 
FFP   Fresh Frozen Plasma 
IVE   Intravenous Fluid 
Sr. Creatinine   Serum Creatinine 
TC   Total count 
WBCT   Whole Blood Clotting Time 
10 
 
CONTENTS 
       
                          
S. NO. 
                                                           
TITLE 
                          
PAGE NO. 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 MATERIALS AND METHODS 72 
5 OBSERVATION AND RESULTS 76 
6 DISCUSSION 96 
7 SUMMARY 99 
8 CONCLUSION 101 
9 ANNEXURES 
 Bibliography 
• Proforma 
• Master Chart 
• Ethical Clearance 
• Turnitin Certificate 
102 
                             
  
11 
 
INTRODUCTION 
                    In many parts of India, snake is worshipped and in some 
areas special prayers are performed. In Northern India on Naga 
Panjami day people worship snake idol. In certain areas of Maharashtra 
and Goa the live snakes, rarely live cobras are brought for worship. 
Snake charmers carry snakes especially cobra, door to door for 
worship. At every house the snake’s mouth is forced open and some 
milk is poured down in its throat though milk is not snake food. It is 
also believed that snakes bite people who harmed them in their 
previous birth. When snakes are killed, people offer special prayers and 
bury them. People also believe that snakes take revenge against those 
who harmed them. 
In view of their strong beliefs and many associated myths, people 
resort to magico-religious treatment for snake bite thus causing delay in 
seeking proper treatment. As a result, valuable time is lost in some of 
the deserving cases. It is poignant to note that some of the cinema and 
TV serial stories even now propagate non-scientific ideas on snakes 
and snakebites, and display traditional treatment. Hence, there is a need 
for the health department to disseminate the scientific aspects related to 
snakebites to the community.  
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AIMS AND OBJECTIVES 
 
1. To study the clinical profile of renal involvement in snake bite 
patients 
2. To study the in-hospital outcome of acute kidney injury in snake 
bite patients 
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                          REVIEW OF LITERATURE 
Magnitude of the problem:- 
 Recently global burden of snake bite was assessed using 
available published data and modeling technique. From that it is 
estimated that 4,21,000 envenomations and 20,000 deaths occur 
annually. These figures may be as high as 18,41,000 envenomations 
and 94,000 deaths. 
 Snake bites contribute to health problem in India and continue to 
be a major medical concern. India alone contributes to 81,000 
envenomations and 11,000 deaths annually. Based on the above 
statistics, it appears that every 10 seconds one individual is envenomed 
and one among four dies due to snake bite. Many deaths occur before 
the victim reaches the hospital. 
          Actually up-to-date national data, on the morbidity and mortality 
due to snakebite is not available. Moreover there is no national snake 
bite registry in India. So the available statistics is incomplete and not 
systematically collected.     
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      In 1972, Dr. Sawai and Dr. Homma of the japan Snake Institute 
studied snake bite in about 10 hospitals in India. They reported that 
about 10% of snake bite deaths are among the victims who come to the 
hospital and about 90% die outside, having gone for other remedies 
like mantra, magic, and so on. However things are very different now, 
after 35 years. 
 Government Rajaji Hospital, Madurai from June to Oct 2014 has 
treated 281 Cases of snake bites. Among them, there were 182 males 
and 99 females. 94 were referred after treatment in different hospitals 
and 187 were brought to the hospital directly. 274(97.5%) survived and 
7 died due to various complications, number referred, number who 
received supportive Theraphy and death are provided below (Table 
no.1). 
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Table No.1: Statistics on clinical aspects of snake bites and outcome 
 
 
Type of 
snake 
 
Numbe
r 
treated 
 
Loca
l 
signs 
 
Neuro 
Toxicit
y 
 
Hemo- 
Toxicit
y 
 
Supportive 
 
 
Numbe
r 
Expire
d 
Mechanica
l  
ventilation  
Hemo- 
Dialysi
s 
Fasciotom
y 
Cobra 118 80 118 - 90 - - 2 
Krait 82 - 51 82 60 3 - 2 
Russell’s 
Viper 
42 42 - 42 6 23 1 1 
Hump- 
nosed  
Viper 
4 4 - 4 - 4 - 1 
Saw 
scaled 
viper 
16 16 - 16 - 3 - 1 
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Sea  
Snake 
3 3 - - - - - - 
Non 
poisonou
s 
16 6 - - - - - - 
 
An equal or more numbers of snake bite cases were admitted and 
treated at other Government Medical College Hospitals. Patients go to 
private hospitals mostly for first aid purposes. Very few get adequate 
treatment in these hospitals. 
The Government is spending a huge sum of money in procuring and 
supplying anti snake venom. On an average, Government hospitals 
spend a minimum of Rs.5,000/- per case of Snake bite and patient 
spend an equal amount for socio-cultural and magico-religious aspects. 
The money lost due to loss of job and earning as well as loss of lives is 
huge, and thus has an impact on the national economy. Deaths due to 
snake bite can be prevented, if some simple first aid measures are 
undertaken by the public and / or by the health care providers. So, there 
is an urgent need to take effective steps to contain these issues. 
17 
 
 Many of the first aid measures carried out at present are 
ineffective and dangerous. The research also concluded that the other 
traditional methods followed for snake bite are not appropriate. It is 
gratifying to note that the traditional snake catchers in Tamil Nadu, the 
Irulas with their own sophisticated herbal medicine system, have now 
understood the problems? They know that the snake injects venom 
which goes deep into the system and this can be neutralized only by 
injection of Anti snake venom (ASV) and not by oral or locally applied 
remedies, no matter how famous. But this information needs to reach 
other communities also. 
 Hence, the need to recommend the most effective first aid to the 
victims bitten by snakes and to recommend effective steps in the 
management of this problem. Poisoning due to cobra and viper groups 
are seen frequently in the state of Tamil Nadu. Very rarely Sea snake 
bite cases are reported. Hence, this hand book focuses on the first two. 
Though the specific antidote is not available  for sea snake, the same 
general principles for other snake bites are applicable here too. 
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Epidemiology of snakebite:- 
Snakebite is observed all over the country with a rural / urban ratio of 
9:1. They are more common during monsoon and post monsoon 
seasons. Snakebites are seen often among agricultural workers and 
among those going to the forest. Many of the susceptible populations 
are poor living below poverty line, living in rural areas with less access 
to health care.  
The male / female ratio among the victims is approximately 3:2. 
Majority  are young and their age is between 25 to 44 years. Most of 
the bites (90 to 95%) are noticed on the extremities (limbs). The 
hospital stay varies from 2 to 30 days, with the median being 4 days. 
The in-hospital mortality varies from 5 to 10%, and the causes are 
acute renal failure, respiratory failure, sepsis, bleeding and others. 
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Ecological aspects: 
 By destroying forests for creating agricultural land, the prey base 
of the snake (that is frogs and rats) has increased. The rice fields, which 
harbor millions of rats attract a lot of snakes. The number of snakes per 
acre in a rice field is abnormally high when compared to the natural 
population in the forest. Humans go into the field every morning and 
come out in the evening, just the time when snakes are active. Thus, the 
chance of an encounter between farmer and snake is very high. As 
more areas are inhabited at the periphery of towns, even there the 
chances of human / snake interaction increase. 
 Cobras flourish as long as there are rice fields; there they feed 
mainly on the mole rat (varapu eli in Tamil), live and lay their eggs in 
the rat burrow networks. Kraits also get by very well in rice fields 
because they like the plentiful small rodents such as the field mouse 
(sundeli in Tamil) and rock mouse (Kallu eli in Tamil). Kraits are also 
found in the mounds of earth and rubble near wells.  
            The Russell’s viper lives in the rocky outcrops and hedgerows 
of cactus and other bushes which often form the boundaries of 
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agricultural land. There, on the high ground, they have a plentiful 
supply of common gerbil (Velleli in Tamil) which are also attracted to 
the wealth of food humans provide by their farming activities! But 
thanks to snakes, we are not overrun by rodents. 
Classification of Snakes:- 
 There are more than 3000 spices of snakes in the world. For the 
purpose of clinical practice, snakes are classified into poisonous 
(venomous) and non-poisonous (nonvenomous) snakes. Poisonous 
snake are classified into three families and they are  
 Cobra group [Elapidae] 
 Viper group [Viperidae] 
 Sea snake group [Hydrophidae] 
For many decades, the concept of the “Big 4” snakes of medical 
importance has reflected the view that 4 spices and responsible for 
Indian snakebite mortality. They are the Indian Cobra (Naja naja), the 
comman Krait (Bungarus caeruleus), the Russell’s viper (Daboia 
russelii) and the Saw scaled viper (Echis carinatus). However, recently 
another species, the Hump-nosed pit viper (Hypnale hypnale), has been 
found to be capable of causing lethal envenomation, and that this 
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problem had been concealed by systematic misidentification of this 
species as the saw-scaled viper.  
The concept of the “Big 4” snakes has failed to include all 
currently known snakes of medical significance in India. This has a 
negative effects on clinical management of snakebite and the 
development of effective snake anti venoms. 
Table No.2: Categorisation of snakes (W.H.O. 1981) 
Class Details Name of the snakes 
I 
Commonly cause 
death or serious 
disability 
Russell’s viper / 
Cobra / Saw scaled 
viper 
II 
Uncommonly cause 
bites but are recorded 
to cause serious effects 
(death or local 
necrosis) 
Krait / Hump-nosed 
pit viper / King cobra 
/ Mountain pit viper 
III 
Commonly cause bites 
but serious effects are 
very uncommon. 
Water snakes, Green 
snakes 
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DIFFERENT TYPES OF SNAKES 
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Snakes of Medical Importance in Tamil Nadu – Distinguishing 
features:- 
 A great deal is written concerning the problem of how to identify 
medically significant species from non-significant ones. A large 
amount of space is devoted, in both medical and toxicology textbooks, 
to the problem of how to identify venomous snakes. The problem with 
this information is that it is complex (involves counting of scales) and 
not definitive (the identification of pre or post maxillary teeth) and of 
no use to a doctor in a medical situation. On the question of 
description, it is worth remembering that the least reliable means of 
identifying a particular species of snake is to use color.  
          Virtually every species of venomous snake has a huge range of 
color manifestations and even the markings can be subjected to major 
variations. What is important therefore is to focus on the key aspects of 
identification that enable the medical professional to rapidly identify 
whether they are dealing with a venomous species, and what that 
species might be. 
Russell’s viper (Daboia russelii):- 
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       The Russell’s viper is a stout bodied snake, the largest of which 
grows to approximately 1.8 meters in length. Like all vipers it is a 
nocturnal snake, but unfortunately for humans, during the daytime it 
rests up under bushes, at the base of trees and in leaf litter. It is 
therefore frequently encountered by rural workers, as they are carrying 
out general agricultural activities. 
         There are two key identification features that are worth nothing. 
The first is a series of chain –like or black edged almond shaped marks 
along the snakes back and flanks. The second distinguishing mark is a 
white triangular mark on the head with the apex of the triangle pointing 
towards the nostrils. 
Saw scaled Viper:-         
 The southern Indian Saw Scaled Viper is a small snake, usually 
between 30 and 40 centimeters long. The Northern Indian species 
(Echis sochureki) is much larger, with an average size of 60 
centimeters. It in habits mainly dry arid climates but can also be found 
in scrub land.  
 One of the key identification features of this species is the 
posture it adopts when it is agitated. It moves its body into a figure of 
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eight like arrangements with its head at the center. It rapidly moves its 
coils against each other and produces a hissing like sound which gives 
its name of ‘Saw scaled’ in addition, there are often wavy hoop like 
markings down both sides of the saw scales body. On the head, there is 
usually a white or cream arrow shaped mark, pointing towards the front 
of the head, often compared to the shape of the birds foot. 
The Hump-Nosed Pit Viper (Hypnale hypnale):- 
 The hump nosed pit viper is one of India’s tiniest venomous 
snakes, its total length ranging from 28.5 to 55cm. Its distinctive 
features include the presence of five large symmetrical plate scales on 
the top of the head in addition to the smaller scales typical of all vipers. 
There are heat sensitive pits between the nostril and the eye. 
Spectacled Cobra (Naja naja):- 
 The spectacle Cobra, is probably India’s most well recognized 
snake. The hood markings of the spectacle like mark, distinguishes this 
snake from other species, and its habit of rearing up when alarmed 
makes it distinctive but not definitive as other species do this, notably 
the Trinket snake. The cobras coloration may vary from pale yellow to 
black. 
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Common Krait (Bungarus caeruleus):- 
 The Common krait is a nocturnal snake which usually grows to 
approximately 1.0 to 1.2 meters in length. Its primary diet is other 
snakes. It can be found all over peninsular India and often seeks 
habitation near human dwellings. During the day it rest up in piles of 
bricks, rat burrows or other buildings. The common krait is the most 
poisonous snake in India and its venom is pre-synaptic neurotoxic in 
nature. 
 There are number of key identifiers which are worth 
remembering. The krait is black, sometimes with the bluish tinge, with 
a white belly. Its markings consist of paired white bands which may be 
less distinct anteriorly. These paired white bands distinguish the snake 
from another black nocturnal snake, The Common wolf snake. The 
wolf snake’s white bands usually are thicker and are singular bands 
equidistant from each other. The useful distinguishing feature is a 
series of hexagonal scales along the top of the snakes back. This 
feature is really useful if the dead snake has been brought to the 
hospital and examined. 
King Cobra:- 
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 The King Cobra is the least medically significant of the 
venomous snakes in India in terms of both bites and fatalities. Hence, 
descriptive features of this are not provided here. 
 
 
Clinical aspects of Snake Bite:- 
 Snake venom is mostly watery in nature. It consists of numerous 
enzymes, proteins, amino acids, etc., Some of the enzymes are 
proteases, collagenase, arginine ester hydrolase, hyaluronidase, 
phospholipidase, metallo-proteinases, endogenases, autocoids, 
thrombogenic enzymes, etc.,  These enzymes also act like toxins on 
different tissues of the body, and are grouped under neurotoxins, 
nephrotoxins, hemotoxins, cardiotoxins, cytotoxins etc., resulting in 
organ dysfunction / destruction. Enormous clinical and experimental 
works have been published on the pathophysiology of snake bite in 
relation to different species of snakes 
 Hyaluronidase allows rapid spread of venom through 
subcutaneous tissues by disrupting mucopolysaccharides, and 
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phospholipase A2 has esterolytic effect on the red blood cell membrane 
and causes hemolysis. It also promotes muscle necrosis.  
        Thrombogenic enzymes promote formation of weak fibrin clot, 
which activities plasmin and results in consumptive coagulopathy and 
hemorrhagic consequences. Venom of some snakes causes 
neuromuscular blockade at pre or post synaptic level. 
          In addition to above it causes endothelial cell damage which 
results in increased vascular permeability. In short, snake venom acts 
on various parts / systems / organs of the body. Venom also causes 
endothelial cell damage which results in increased permeability. 
Symptoms and signs:- 
 An international expert on snakebite, the late Dr. Alistair Reid of 
the Liverpool School of Tropical Medicine found out that only 10 to 
15% of venomous bites end in death. The possibility of survival, even 
without treatment, is incredibly good in 80-90% of cases. One of the 
reasons for this is that much snakebite are by non-venomous snakes. 
Secondly, a large percentage of venomous snakebites are dry bites i.e., 
the snake does not always inject venom. Sometimes, it might inject 
only a tiny quantity of venom.  
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       The snake can inject the quantity of venom it wants. This is an 
entirely voluntary process. Hence, one can never know how much 
venom was injected except by observing the progression of the 
symptoms. In other words the recovery in snakebite without even 
treatment is great. Every traditional healer uses this fact to his / her 
advantage and propagates his /her own method to treat snakebite viz., 
herbal details, “snakestone” or mantra, or plain soda water and most 
villagers would be happy to go to him.  
 Also, everyone should remember the systemic action of venom 
and the extent varies from one snake to another. Complications and 
outcome due to snakebite may also vary from each other and can’t be 
predicted by any means.  
           Moreover, the status of poisoning cannot be judged by the bite 
mark, reaction to envenomation, size or the type of snake. Hence, one 
has to observe for signs and symptoms which may develop within 24 to 
48 hours. The symptoms and signs of Viperine and Elapid 
envenomation as well late-onset envenomation are listed below. 
General symptoms and signs of Viperine envenomation:- 
Local effects 
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Swelling and local pain with or without erythema or 
discoloration at the site if bite. 
 Tender enlargement of local lymphnodes as large molecular 
weight Viper venom molecules enter the system via the 
lymphatics. 
 Effects due to coagulopathy and hemorrhagic consequences 
 Bleeding from the gingival sulci and other orifices. 
 Epistaxis. 
 The skin and mucous membranes may show evidence of 
petechiae, purpura and ecchymoses. 
 The passing of reddish or dark-brown urine or declining or no 
urine output. 
 Lateralising neurological symptoms and asymmetrical pupils 
may be indicative of intra-cranial bleeding. 
 Vomiting. 
 Acute abdominal tenderness which may suggest gastro-intestinal 
or retro peritoneal bleeding. 
 Hypotension resulting from hypovolaemia or direct vasodilation. 
 Low back pain, indicative of early renal failure or retroperitoneal 
bleeding. 
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Other effects:- 
 Muscle pain indicating rhabdomyolysis. 
 Parotid swelling, conjunctival oedema, sub-conjunctival 
haemorrhage. 
 General symptoms and signs of  Elapid envenomation:- 
Local effects:- 
 Swelling and local pain with or without erythema or 
discoloration at the site if bite.(Cobra). 
 Local necrosis and / or blistering / (Cobra). 
Neurotoxic effects 
 Descending paralysis, initially of muscles innervated by the 
cranial nerves, commencing with ptosis, diplopia, or 
ophthalmoplegia. The patient complains of difficulty in focusing 
and the eyelids feel heavy. There may be some involvement of 
the senses of taste and smell. 
 Problems of vision, breathing and speech. 
 Paralysis of jaw and tongue may lead to upper airway 
obstruction and aspiration of pooled secretions because of the 
patient’s inability to swallow. 
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 Numbness around the lips and mouth, progressing to pooling of 
secretions, bulbar paralysis and respiratory failure. 
 Hypoxia due to inadequate ventilation can cause cyanosis, 
altered sensorium and coma. This is a life threatening situation 
and needs urgent intervention. 
 Paradoxical respiration, as a result of the intercostal muscles 
paralysis is a frequent sign. 
 Krait bites often present in early morning with paralysis that can 
be mistaken for a stroke. Stomach pain which may suggest 
submucosal haemorrhages in the stomach. 
Other effects 
 Stomach pain which may suggest submucosal haemorrhages in 
the stomach (Krait). 
 Eye pain and damage due to ejection of venom into the eyes by 
spitting cobra(as observer in Africa) 
 [If failure of renal failure are noted search for others causes / 
mechanisms] 
Late-onset envenomation:- 
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 The patient should be kept under close observation for at least 24 
hours. Many species, particularly the Krait and the Hump-nosed pit 
viper are kown for the length of time it can take for symptoms to 
manifest. Often this can take between 6 to 12 hours. Late onset 
envenoming is a well-documented occurrence. This is also particularly 
pertinent at the start of the rainy season when generally give birth to 
their young. Juvenile snakes(young ones), 8-10 inches long, tend to 
bite the victim lower down on the foot in the hard tissue area, and thus 
any signs of envenomation can take much longer to appear. 
Overlapping symptoms and signs:- 
 Russell’s viper envenomation can also manifest with neurotoxic 
features. This can sometimes cause confusion and further work is 
necessary to establish how wide this might be. Development of 
neurotoxic features in Russell’s viper bite are believes to be pre 
synaptic or Krait like in nature. It is for this reason that a doubt is 
expressed over the response of both species to Neostigmine. Clinical 
aspects and therapeutic response in relation to some of the poisonous 
snake in India is provided in Table no. 3 
Table No.3: snakes, clinical aspects and therapeutic response 
34 
 
Feature Cobras Kraits Russell’s Viper 
Saw 
Scaled 
Viper 
Hump 
Nosed 
Viper 
Local 
pain/Tissue 
Damage 
YES NO YES YES YES 
Ptosis / 
Neurological 
Signs 
YES YES YES! NO NO 
Haemostatic 
abnormalities 
NO* NO! YES YES YES 
Renal 
Complications 
NO NO* YES NO* YES 
Response to 
Neostigmine YES NO? NO? 
NOT 
applicable 
NOT 
applicable 
Response to 
ASV 
YES YES YES YES NO 
 
Sea snakes:- 
 Sea snake bites are reported rarely among fishermen and / or 
their family members living in the seashore area as well as among 
those who walk on the seashore. To begin with there may be local pain 
which may be insignificant which appears within 60 to 90 minutes. 
There may not be obvious local swelling. Systemic manifestations 
noticed among poisonous sea snake bite are neurological involvement, 
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severe muscle pain, rightly, renal failure, hyperkalemia and finally 
cardiac arrest. 
Criteria for diagnosis:- 
Table No. 4: Details of local envenomation 
 Pain-pain at the site of bite, swelling and regional lymphnode 
 Oozing - sero / sanguinous oozing from the site of bite 
 Node- development of an enlarged tender lymphnode draining 
the bitten limb 
 Discoloration- discoloration at the site of  bite 
 Swelling – swelling is seen at the site of the bites on the digits 
(toes and especially fingers); local swelling develops in more 
than half of the bitten limb immediately(in the absence of the 
tourniquet) and swelling extends rapidly beyond the site of bite 
(eg. beyond the wrist or ankle within a few hours of bites on the 
hands or feet) 
 
Complications and Outcome: 
 Complications in snake envenomation are due to the hetrogenous 
composition of the venom. In addition the quantity and quality of the 
venom and the response of the individual to the components of venom 
influence the clinical course, complications and outcome. The 
complications of venom are observed in various systems viz., the 
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hematological, vascular, renal, respiratory, cardiovascular, endocrine, 
gastrointestinal muscular and dermatological system. 
 In addition to the anti-snake venom, the envenomed individual 
requires supportive treatment for the complications arising out of 
snakebite as well as the consequences of the complication. One must 
also remember to look for complications developing after infusion of 
Inj. anti snake venom and get prepared to treat them also. 
 The outcome of snakebite depends upon amount of 
envenomation, bite to needle time, individual’s response to 
envenomation, the complications that develop following snakebite and 
response to treatment. Till the patient has recovered, one cannot predict 
the complications and outcome. 
Investigations:- 
Table No. 5: 20 Minutes Whole Blood Clotting Test (20WBCT) 
Advantages Requirements Procedure 
The most reliable test 
of coagulation. 
Can be carried out, at 
Dry glass test 
tube(clean and new) 
2ml disposable 
Wash hands with soap 
and water. 
Wear the gloves 
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the bedside. 
Does not require 
specialized training. 
syringe 
Cotton 
Antiseptic solution 
Clean gloves(one pair) 
(The test tube must 
not have been washed 
with detergent, as this 
will inhibit the contact 
element of the clotting 
mechanism) 
Collect 2ml blood 
from the peripheral 
vein of the unaffected 
limb 
Remove the needle 
and pour the blood 
along the walls of the 
test tube 
Keep the test tube 
untouched and 
unshaken in a safe 
place near the 
patient’s bedside at 
ambient temperature 
for 20 minutes  
Note the time 
After 20 minutes the 
test tube is gently 
tilted and if the blood 
is still liquid then the 
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patient has 
incoagulable blood. 
  
If the 20WBCT is normal in a suspected case of poisonous 
snakebites, the test should be carried out every 30 minutes from 
admission for three and then hourly after that. If incoagulable blood is 
discovered, the 6 hourly cycles will then be adopted to test for the 
requirement of repeat doses of ASV. This is due to the inability of the 
liver to replace clotting factors under 6 hrs. 
Other Useful Tests: 
Clinical test: 
 PP /BP/ RR / Postural Blood Pressure 
Laboratory studies: 
 Haemoglobin /PCV / Platelet Count / PT / APTT/FDP/D-Dimer 
 Peripheral Smear/ Blood grouping/ Rh typing 
 Urine Tests for 
Proteinuria/RBC/Haemoglobinuria/Myoglobinuria 
 Biochemistry for Serum Creatinine/Urea / Electrolytes /  Oxygen 
Saturation 
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Imaging studies: 
 X-Ray Chest /CT / Ultrasound(whenever required) 
Others: 
 Electrocardiogram 
 Special investigations depending upon clinical status 
 Ocular fundus examination 
Treatment: 
First aid for snake bite 
 The first aid currently recommended is based around the 
mnemonic ‘R.I.G.H.T’. 
The details are provided in Table no.6. 
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Table No.6: Currently recommended First aid 
R.=Reassure the patient 
(70% of all snakebites are from non-venomous species. Only 50% of 
bites by venomous species actually envenomate the patient) 
I=Immobilise in the same way as a fractural limb. 
(Use bandage or cloth to hold the splints, not to block the blood supply 
or apply pressure. Do not apply any compression in the form of tight 
ligatures, they don’t work and can be dangerous! ) 
G.H.=Get to Hospital Immediately. 
(Traditional remedies have NO PROVEN   benefit in training 
snakebite). 
T=Tell the doctor of any systemic symptoms such at ptosis that 
manifest on the way to hospital. 
 
 This method will get the victim to the hospital quickly, without 
recourse to traditional medical approaches which can delay effective 
treatment. 
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Traditional first aid methods followed for snakebite: 
 The traditional methods such as application of tourniquet, cutting 
(incision) and suction, washing the wound, snake stone or other 
methods have adverse effects and hence, they have to be discarded. 
The mneumonic used to recall some of the traditional methods 
followed is “WHISTTLE” and these are described below. 
Washing the Wound: 
 Victims and bystanders have a tendency to wash the wound to 
remove any venom on the surface. This should not be done as the 
action washing increases the flow of venom into system by stimulating 
the lymphatic system. 
Household remedies: 
 Various forms of household remedies are applied to the site of 
bite which may enhance absorption of venom. 
(Incision)Cutting and Suction: 
 Cutting the site of bite and suctioning incoagulable blood 
increases the risk of bleeding to death as well as increases the risk of 
infection. Venom is not cleared or removed from the snakebite by this 
method. 
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Snake stone: 
 Snake stone is applied to the site of bite saying that it will absorb 
the venom and falls once the venom is absorbed. This contributes to 
delay in seeking appropriate health care. 
Tourniquets: 
 Tight tourniquets made of rope, string and cloth, have been 
followed traditionally to stop venom flow into the body following 
snakebite. The problems noticed with tourniquets are:- 
 Risk of ischemia and loss of the limb 
 Risk of necrosis 
 Risk of massive neurotoxic blockade 
 Risk of embolism if used in viper bites 
 Release of tourniquet may lead to hypotension 
 Gives patient a sense of false security, which encourages them to 
delay their journey to hospital 
Treatment:- 
 While dealing with a case of snake bite consider the mnemonic 
‘RASI’ 
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 Remember principles(“12 As”) 
 Address the problems – clinical and social 
 Seek help from others when required and 
 Inform the patient and/or case givers on the status of illness, 
clinical course, management, outcome, welfare measures and 
follow up clearly with empathy. 
Principles involved in the management of snake bite:- 
 The principles while managing cases of snake bite at any Health 
Centre are clubbed under “12 As” 
Table No.7: Principles involved in the management 
1. Admit the victim immediately 
2. Ask effectively 
3. Assess quickly 
4. Act swiftly 
5. Administer medication meticulously. 
6. Address to the wound properly 
7. Anticipate complications keenly 
8. Avoid errors carefully 
9. Ascertain the status repeatedly 
10. Amicable with patients and care givers and show empathy 
11. Advise on follow up accordingly 
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Pharmacological aspects of Anti snake venom:- 
 The goals of pharmacotherapy with injection Anti snake venom 
(ASV) are to neutralise the venom, reduce morbidity and mortality, and 
prevent complications. Currently available Anti Venom (ASV) in India 
polyvalent i.e., it is effective against all the four common species; 
Russell’s viper (Daboia russilii,) common Cobra (Naja naja), Common 
Krait (Bungarus caeruleus) and Saw Scaled Viper (Echis carinatus).  
Indian ASV is a F (ab)2 product derived from horse serum and has a 
half-life of  over 90 hours. Though it is purified, it still can be 
immunogenic. 
 At present, no monovalent ASV is available primarily because 
there are no objective means of identifying the snake species, in the 
absence of the dead snake. Moreover it is difficult for the physician to 
determine which type of Monovalent ASV to employ in treating the 
patient. In addition there are difficulties to prepare, supply and 
maintain adequate stock of species monovalent ASV. 
 There are other known species such as the Hump-nosed pit viper 
(Hypnale hynale) where polyvalent ASV is known to be ineffective. 
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 In India ASV is manufactured by Bengal Chemicals & 
Pharmaceuticals, Kolkata; Bharat Serums, Mumbai; Biological Events, 
Hyderabad; Central ResearchInstitute, Kausali; Haffkins 
Pharmaceuticals, Mumbai; King Institute of preventive medicine, 
Chennai; Pune and Vins bio-products, Hyderabad. 
ASV Administration:- 
Criteria 
 ASV is prepared from animal and hence, it should only be 
administered when there are definite signs of envenomation. Anti-
Snake Venom carries risks of anaphylactic reactions and should not 
therefore be used unnecessarily. Unbound, free flowing venom, can 
only be neutralized when it is in the bloodstream or tissue fluid. Also it 
is a scarce and costly commodity. Hence, ASV may be administered 
only if a patient develops one or more of  the following signs/ 
symptoms. 
Systemic envenoming:- 
Evidence of coagulopathy primarily detected by 20 WBCT or 
visible spontaneous systemic bleeding, bleeding gums, etc., Further 
laboratory tests for thrombocytopenia, HB abnormalities, PCV, 
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peripheral smear etc may provide confirmation, but  20 WBCT  is 
paramount. 
 Evidence of neurotoxicity: ptosis, external ophthalmoplegia, 
muscle paralysis, inability to lift the head etc., 
 Cardiovascular abnormalities: hypotension, shock, cardiac 
arrhythmia, abnormal ECG. 
 Persistent and severe vomiting or abdominal pain. 
 Local envenomation (Refer Table No: 4) 
 Purely local swelling, even if accompanied by a bite mark from 
an apparently venomous snake, is not grounds for administering ASV 
if a tourniquet or tourniquets have been applied. These themselves can 
cause welling. Once they have been removed for 1 hour and the 
swelling continues, then it is unlikely to be as a result of the tourniquet 
and administration of ASV may be justified. 
Dosage 
 The recommended dosage level has been based on published 
research that Russell’s viper injects on average 63mg  (SD 7) of 
venom. Logic suggests that our initial that the majority if victims 
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should be covered by the initial dose and keeps the cost os ASV to 
acceptable levels. The range of venom injected is 6mg to147mg. 
 One vial of ASV neutralizes 6mg of Russell’s viper venom. So, 
to neutralize 63mg of venom, 10 vials are needed.  Not all victims will 
require 10 vials as some may be injected with less than 63mg.  
 They may also pre-sensitise the patient and thereby create 
greater risk.  For Neurotoxic /Anti Haemmostatic envenomation, 8 to 
10 vials of ASV is recommended to be administered as in initial dose.  
Children receive the same ASV adults, as snakes inject the same 
amount of venom into adults and children. The ASV targeted at 
neutralizing the venom. 
Administration:- 
ASV may be administered in two ways over a period of one hour 
at a constant speed and the patient should be closely monitored for 2 
hours: 
Infusion: liquid or reconstituted ASV is diluted in 5-10ml/kg 
body weight of isotonic saline or glucose and administered as infusion 
usually.(Fluid requirement for children refer to Annexure II) 
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Intravenous Injection: Rarely reconstituted or liquid ASV is 
administered by slow intravenous injection.(2ml/ minute). Each via Iis 
10ml of reconstituted ASV. 
Facts to be remembered before/ while using of Anti Snake Venom 
(ASV):- 
1. ASV is available in a polyvalent form and marketed I liquid or 
lyophilized preparations in 10ml vial/ampoule. 
2. Remember to use and maintain cold coin system for liquid form. 
Users are informed to ascertain whether the cold chain is 
maintained. 
3. ASV treatment should not be initiated without adequate agents 
for managing anaphylaxis or anaphylactoid reaction. 
4. Anaphylactic or late serum sickness cannot be determined or 
prevented by test dose. 
5. ASV neutralizes the unbound venom, hence give it early. 
6. ASV administration should not be delayed or denied on the 
grounds of anaphylactic reactions to a deserving case. 
7. ASV required only to those who show definite signs and 
symptoms of envenomation. 
8. No interaction with ASV has been reported 
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9. Fetal risk due to ASV has not been established or studied in 
humans. 
10. Safely status for use of ASV during pregnancy has not been 
established. 
ASV Reactions:- 
Reactions to ASV develop usually within 15 to 30 minutes or 
within 2 hours. So monitor the case on ASV at 5min. interval for first 
30 min. and then at 15min. interval for two hours. The details of pre 
hospital treatment and issues related to ASV may be recorded in the 
form provided in Annexure IV. 
Sometimes, anaphylaxis (Type I) following ASV may develop 
rapidly and deteriorate into a life-threatening emergency, and hence 
anticipate and observe for it in every case. If the correct guidelines are 
followed, anaphylaxis can be effectively treated. 
Table No. 8: Manifestations if immediate reactions to ASV 
Itching(often over the scalp) 
Urticaria, even a single spot 
Nausea 
Vomiting 
Abdominal colic/pain 
Dry cough 
Bronchospasm /rhonchi 
Stridor(rarely) 
Angio-oedea of lips and 
mucous membrane 
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Diarrhoea 
Tachycardia(PR>120/min)(for 
children refer age specific chart) 
Fall in blood pressure 
Low volume pulse 
 
Fever 
Shaking chills(rigors) 
Sweating 
Cold and clammy skin 
Central cyanosis 
Febrile convulsions(in children) 
Anaphylaxis 
Treatment for ASV reactions:- 
 Discontinue ASV 
 Maintain  IV line 
Administer Inj. Adrenaline 0.5ml of 1:100 IM,(Adults)/Inj. 
Adrenaline 0.1ml/kg body weight of 1:10,000 IM (paediatric 
dose).Details are provided in Table No:9 
A second dose of 0.5ml of Adrenaline IM is given. This can be 
repeated for a third and final occasion but in the vast majority of 
reaction 2 doses of adrenaline will be sufficient 
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Table No.9: Dosage of adrenaline for adults and children 
Adults *Children (upto 25kg ) 
Inject adrenaline 1:1000 
intramuscularly: 
Weighting<50kg give 0.25ml 
Weighting 50-100kg give 0.50ml 
Weighting >100kg give 0.75ml 
Inject adrenaline 1:1000 dilute 
Lampoule (1ml) of adrenaline 
1:1000 with 9ml water for 
injection or normal saline. 
Inject intramuscularly 1:10.000 
adrenaline according to the guide 
(approximates to 0.1ml/kg). 
1year(10kg)give 1ml 
3year(15kg)give 1.5ml 
5year(20kg)give 2ml 
8years(25kg)give2.5ml 
Children>25kg as for small adults 
 
Approximate body weight for children may be calculated by the 
formula; 
2x Age+9=weight in kg 
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Consider additional measures:- 
Administer Salbutamol or Terbutaline by aerosol or nebulizer 
(Beta 2 agonists) for bronchospasm 
Antihistamines: Administer both H1 receptor blockers Inj. 
Chlorpheniramine maleate 10-20mg as Iv/Intramuscularly or 
promethazine 0.5-1mg/kg and H2 receptor blockers Inj. Ranitidine 
1mg/kg or Famotidine 0.4mg/kg or cimetidine 4mg/kg slowly 
intravenously. 
Administer corticosteroid intravenously: Hydrocortisone 2- 6 
mg/kg or Dexamethasone 0.1- 0.4mg/kg. 
Try nebulised Adrenaline (5ml of 1:1000) in case of laryngeal 
oedema which often will ease upper airways obstruction. However, do 
not delay intubation if upper airways obstruction is progressive. 
 IV fluids should be given for haemodyamic instability 
Once the patient has recovered, the ASV can be restarted slowly 
for 10-15 minutes. Keeping the patient under close observation. Then 
the normal drip rate should be resumed. 
Monitor vitals and provide supportive measures 
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Late Serum sickness reactions (delayed hypersensitivity) to ASV:- 
 Serum sickness may occur one to two weeks after administration 
of ASV. Late Serum sickness reactions can be easily treated with an 
steroid such as prednisolone, adults 5mg 6 hourly, paediatric dose 
0.7mg/kg/day.(Duration of treatment has to be adjusted with case). 
Oral H1 Antithistamines provide additional symptomatic relief. 
Prevention of ASV Reactions- Prophylactic Regimens:- 
 The conclusion in respect of prophylactic regimens to prevent 
anaphylactic reactions is that there is no evidence from good quality 
randomized clinical trials to support their routine use. If they are used 
then the decision must rest on other grounds, such as policy in the case 
of hospitals, which may opt for a maximum safety policy, irrespective 
of the lack of definitive trial evidence. 
Two prophylactic regimens normally recommended are given 
below: 
100mg of Hydrocortisone and H1 antihistamine (10mg 
Chlorphenimarine maleate; or 22.5mg IV) Phenimarine maleate IV or 
25mg. Promethazine hydrochloride IM) 5minutes before ASV 
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administration. The dose for children is 0.1-0.3mg/kg of antihistamine   
IV and 2mg/kg of Hydrocortisone IV. 
0.25-0.3mg Adrenaline 1:1000 given gives subcutaneously. 
If the victim has a known sensitivity to ASV, pre-medication 
with adrenaline, hydrocortisone and anti-histamine may be advisable, 
in order to prevent severe reactions.   
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OBSERVATION AND RESULTS 
Study Design: 
A prospective clinical study with 50 snake bite patients is 
undertaken to study the acute Kidney Injury 
Table 1: Age distribution of patients studied 
 
Age group (years) Number of patients % 
18-30 years 12 24.0 
31-40 years 7 14.0 
41-50 years 16 32.0 
51-60 years 13 26.0 
>60 years 2 4.0 
Total 50 100.0 
 
Mean ± SD: 43.80 ±12.6 
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Figure 1: Age distribution of patients studied 
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Sixteen patients were in the age group of 41–50 years. Mean age 
was 
 
43.8 years. 
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Table 2: Gender distribution of patients studied 
 
Gender Number of patients % 
Male 31 62.0 
Female 19 38.0 
Total 50 100.0 
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Figure 2: Gender distribution of patients studied 
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Out of 50 patients included in this study, 31 were males (62%) 
and 
 
19 (38%) were females. 
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Table 3: Snake bite site of patients studied 
 
Snake bite site Number of patients 
(n=50) 
%  
Side of bite    
Left side 32 64.0  
Right 18 36.0  
Site of bite    
Leg 20 40.0  
Foot 19 38.0  
Toe 5 10.0  
Calf 4 8.0  
Shin 2 4.0  
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Figure 3: Snake bite site of patients studied 
 
 
 
 
 
 
 
All bites were to the lower limb. 32 patients (64%) of patients 
had snake bite to left lower limb. 
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Table 4: Distribution of Lapse of time in hrs of patients studied 
 
Lapse of time 
in hours 
Number of patients % 
0-2 hours 7 14.0 
2-5 hours 18 36.0 
5-12 hours 11 22.0 
12-24 hours 7 14.0 
>24 hours 7 14.0 
Total 50 100.0 
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Figure 4: Distribution of Lapse of time in hrs of patients studied 
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18 (36%) patients presented to the hospital within 2-5 hours of 
snake bite. 
 
Only 7 patients presented after 24 hours of snake bite to the hospital. 
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Table 5: Distribution of Tourniquet application 
of patients studied 
 
Tourniquet 
application Number of patients % 
No 19 38.0 
Yes 31 62.0 
Total 50 100.0 
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Figure 5: Distribution of Tourniquet application of patients 
studied 
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62% had applied tourniquet before coming to the hospital
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Table 6: Identification of snake of patients studied 
 
Identification  
of snake Number of patients % 
Not identified 26 52.0 
Identified   
Viper 23 46.0 
Cobra 1 2.0 
Total 50 100.0 
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Figure 6: Identification of snake of patients studied 
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Among 50 snake bites, only 24 (48%) had identified the snake 
as viper 
 
bites in 23 cases and cobra bite in 1 case. 
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Table 7: Symptoms of snake bite patients 
 
Symptoms 
Number of 
patients (n=50) 
% 
 
Reduced urine output 30 60.0  
Vomiting 19 38.0  
Bleeding from bite site 16 32.0  
Bleeding from the gums 9 18.0  
Hematuria 7 14.0  
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Figure 7: Symptoms of snake bite patients 
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Thirty (60%) patients presented with reduced urine output, 19 
patients (38%) with vomiting, 16 (32%) with bleeding from gums 
and 7 (14%) presented with hematuria. 
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Table 8: Vital statistics of patients studied 
 
Vital statistics Number of 
Patients (n=50) 
%  
Pulse    
<100 43 86.0  
>100 5 10.0  
Not recorded 2 4.0  
Systolic blood pressure mmHg    
<120 34 68.0  
>120 14 28.0  
Not recorded 2 4.0  
Diastolic blood pressure mmHg    
<80 29 58.0  
>80 19 38.0  
Not recorded 2 4.0  
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Figure 8: Vital statistics of patients studied 
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Vital statistics 
 
 
Five patients (10%) had tachycardia and 2(4%) pulse was not 
palpable. Systolic blood pressure (SBP) was ≤120 mmHg in 34 
(68%) and >120 in 14(28%). Diastolic blood pressure (DBP) was 
≤80 mmHg in 29 (58%) and >80 mmHg in 19 (38%). Blood pressure 
was not recordable in 2 patients. 
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Table 9: Clinical manifestations 
 
 
Clinical manifestation 
Number of 
patients (n=50) 
% 
 
Fang mark 47 94.0  
Signs of inflammation 49 98.0  
Bleeding from bite site 16 32.0  
Peripheral pulses not felt 2 4.0  
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Figure 9: Clinical manifestations 
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On local examination 49 (98%) had signs of inflammation, 47 
(94%) had fang mark, 16 (32%) had bleeding from bite site and in 2 
(4%) patients peripheral pulses not felt. 
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Table 10: Hematological parameters of patients studied 
 
Hematological 
Number of 
% Mean ± SD 
 
Patients 
 
parameters 
 
(n=50) 
   
    
Hemoglobin (Hb in 
gms)     
   
9.40±2.08 
 
<10.0% 27 54.0  
     
>10.0% 23 46.0   
     
Total count     
     
<4000 4 8.0 
8013.00±5214.1
3 
 
    
4000-11000 38 72.0 
 
  
     
>11000 8 16.0   
     
Platelet count     
   
1.95±0.83 
 
<1.5 lakh 13 26.0  
     
>1.5 lakh 37 74.0   
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Figure 10: Hematological parameters of patients studied 
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Laboratory data showed anemia with Hb <10 gm% in 27 
(54%), Leukocytosis (Total count >11,000) in 8 (16%) and 
thrombocytopenia (platelet count <1.5 lakh) in 13 (26%) patients. 
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Table 11: WBCT in minutes of patients studied 
 
WBCT in minutes Number of patients % 
   
<20 15 30.0 
   
>20 35 70.0 
   
Total 50 100.0 
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Figure 11: WBCT in minutes of patients studied 
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Whole Blood Clotting Time (WBCT) was >20 minutes in 35 (70%) 
 
Patients. 
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Table 12: Bleeding time of patients studied 
 
Bleeding time 
Number of patients 
% 
 
(n=50) 
 
   
    
Normal 42 84.0  
    
Abnormal (Increased) 8 16.0  
    
Total 50 100  
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Figure 12: Bleeding time of patients studied 
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Bleeding time was prolonged in 8 (16%) patients  
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Table 13: Levels of Blood urea of patients studied 
 
Blood urea Min – Max Mean ± SD 
P value from  
baseline 
 
    
     
Baseline 15.00-198.00 61.01±39.99 -  
     
24 hours 29.00-192.00 81.92±40.75 <0.001*  
     
2nd day 22.00-188.00 74.26±42.69 0.016  
     
3rd day 17.00-196.00 64.83±41.45 0.668  
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Figure 13: Levels of Blood urea of patients studied 
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Mean levels of blood urea at baseline, at 24 hours (p value 
<0.001), on 2nd day and 3rd day were 61.01 mg/dl, 81.92 mg/dl, 74.26 
mg/dl and 64.83 mg/dl respectively 
 
 
Table 14: Levels of Serum creatinine of patients studied 
 
Serum creatinine Min - Max Mean ± SD 
P-value from  
baseline 
 
    
     
Baseline 0.30-20.00 2.32±3.30 0  
     
24 hours 0.90-21.00 3.02±3.58 <0.001**  
     
2nd day 0.60-21.00 2.94±3.72 0.016  
     
3rd day 0.60-18.00 2.52±3.24 0.472  
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Figure 14: Levels of Serum creatinine of patients studied 
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Mean levels Serum Creatinine at baseline, at 24 hours (p-value 
<0.001), on 2nd day and on 3rd day were 2.32 mg/dl, 3.02 mg/dl, 2.94 
mg/dl and 2.52 mg/dl respectively. 
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Table 15: Creatine kinase of patients studied 
 
Creatine kinase 
Number of 
% 
 
patients 
 
   
    
Normal (Male: 25-90 U/L; Female 10-70 
U/L) 0 0.0  
    
Raised (Male >90 U/L; Female >70 U/L) 50 100.0  
    
Total 50 100.0  
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Figure 15: Creatine kinase of patients studied 
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All patients included in the study had elevated serum creatinine 
kinase levels with a mean of 266.58 U/L (Mean ± SD: 266.58±122.53). 
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Table 16: PT INR and APTT of patients studied 
 
 Number of patients 
% 
 
 
(n=50) 
 
   
    
PT INR    
0.8-1.2 33 66.0 
   
>1.2 17 34.0 
   
APTT   
   
<28.0 6 12.0 
   
>28.0 44 88.0 
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Figure 16: PT INR and APTT of patients studied 
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PT-INR was prolonged (>1.2 seconds) in 17 (34%) patients and 
APTT was prolonged (>28 seconds) in 44 (88%) of patients. 
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Table 17: USG abdomen of patients studied 
 
USG abdomen 
Number of patients
% 
 
(n=50) 
 
   
    
Normal 33 66.0  
    
Abnormal (MRD) 17 34.0  
    
Total 50 100  
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Figure 17: USG abdomen of patients studied 
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USG abdomen was normal in 33 (66%) patients and was 
abnormal in 17 (34%) patients showing alteration in cortical 
echotexture with normal kidney size. 
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Table 18: Urine output in ml/day of patients studied 
 
Urine output 
Min - Max Mean ± SD 
P value from  
in ml baseline 
 
   
     
Baseline 15.00-4000.00 1205.40±1010.72 -  
     
24 hours 50.00-3500.00 1433.67±945.29 <0.001**  
     
2nd day 60.00-3000.00 1742.20±929.42 <0.001**  
     
3rd day 100.00-3500.00 1981.00±874.98 <0.001**  
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Figure 18: Urine output in ml/day of patients studied 
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Mean levels of urine output at baseline, at 24 hours, on 2nd day 
and on 3rd day were 1205.40 ml/day, 1433.67 ml/day, 1742.20 
ml/day and 1981 ml/day respectively with significant p value 
(<0.001). 
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Table 19: ASV vials given for patients studied 
 
ASV vials given Number of patients % 
   
Not given 10 20.0 
   
1 to 10 7 14.0 
   
11 to 20 20 40.0 
   
21 to 30 11 22.0 
   
>30 2 4.0 
   
Total 50 100.0 
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Figure 19: ASV vials given for patients studied 
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Twenty patients (40%) received 11-20 vials of ASV and ≥30 
vials of ASVwere given only for 2 patients. 
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Table 20: Supportive treatment of patients studied 
 
Supportive treatment 
Number of patients
% 
 
(n=50) 
 
   
    
IVF 50 100.0  
    
Antibiotics 48 96.0  
    
FFP 3 6.0  
    
Platalets 1 2.0  
    
Whole blood 4 8.0  
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Figure 20: Supportive treatment of patients studied 
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Supportive treatment 
 
 
All patients received Intravenous fluid (IVF) and 48 patients 
(96%) received antibiotics as supportive treatment. 7 patients were 
transfused blood and blood products. 3 patients (6%) were transfused 
FFP, 4 (8%) were transfused whole blood and one patient received 
platelets transfusion. 
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Table 21: Need for hemodialysis of patients studied 
 
Need for hemo 
dialysis Number of patients % 
   
No 44 88.0 
   
Yes 6 12.0 
   
Total 50 100.0 
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Figure 21: Need for hemodialysis of patients studied 
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Among 50 patients 6 (12%) required hemodialysis. 
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Table 22: End results of snake bite patients studied 
 
End results Number of patients % 
   
Improved 43 86.0 
   
CKD 4 8.0 
   
Death 3 6.0 
   
Total 50 100.0 
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Figure 22: End results of snake bite patients studied 
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Out of 50 patients studied, 43 (86%) improved and 7 had a 
poor outcome. Among those 7, 4 patients developed Chronic Kidney 
Disease (CKD) and 3 patients succumb to death. 
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Table 23: Association of clinical variables according to outcome  
Clinical variables 
Outcome 
P-value 
 
   
Good Poor  
 (n=43) (n=7)   
Age in years     
<40 18(41.9%) 1(14.3%) 
0.229 
 
>40 25(58.1%) 6(85.7%) 
 
  
Gender     
Male 27(62.8%) 4(57.1%) 
1.000 
 
Female 16(37.2%) 3(42.9%) 
 
  
Site of bite     
Leg 18(41.9%) 2(28.6%) 0.687  
Foot 14(32.6%) 5(71.4%) 0.093+  
Toe 5(11.6%) 0(0%) 1.000  
Calf 4(9.3%) 0(0%) 1.000  
Shin 2(4.7%) 0(0%) 1.000  
Lapse time in hrs     
0-2 hours 7(16.3%) 0(0%)   
2-5 hours 18(41.9%) 0(0%)   
5-12 hours 10(23.3%) 1(14.3%) 0.005**  
12-24 hours 4(9.3%) 3(42.9%)   
>24 hours 4(9.3%) 3(42.9%)   
Alternative treatment     
No 40(93%) 2(28.6%) 
<0.001** 
 
Yes 3(7%) 5(71.4%) 
 
  
Identified snake     
Not identified 24(55.8%) 2(28.6%) 
0.239 
 
Identified 19(44.2%) 5(71.4%) 
 
  
Tourniquet application     
No 16(37.2%) 3(42.9%) 
1.000 
 
Yes 27(62.8%) 4(57.1%) 
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Comparison between good outcome (recovered from AKI) and 
poor outcome (not recovered from AKI) shows significant p-value 
for ‘lapse of time in hours’ in presenting to the hospital after snake 
bite (p-value 0.005) and ‘alternative treatment taken’ before coming 
to the hospital (p-value 0.001). 
Table 24: Association of clinical symptoms according to outcome 
 
 Outcome   
Clinical symptoms 
  
P value 
 
Good Poor 
 
   
 (n=43) (n=7)   
     
Signs of inflammation 42(97.7%) 7(100%) 1.000  
     
Reduced urine output 24(55.8%) 6(85.7%) 0.219  
     
Vomiting 15(34.9%) 4(57.1%) 0.404  
     
Bleeding from bite site 15(34.9%) 1(14.3%) 0.406  
     
Bleeding from the 
gums 8(18.6%) 1(14.3%) 1.000  
     
Hematuria 5(11.6%) 2(28.6%) 0.250  
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Figure 23: Association of clinical symptoms according to outcome 
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Table 25: Association of Lab parameters according to outcome  
Lab parameters 
Outcome 
P value 
 
   
Good 
(n=43) Poor (n=7) 
 
   
     
PT INR     
0.8-1.2 33(76.7%) 2(28.6%) 
0.020* 
 
>1.2 10(23.3%) 5(71.4%) 
 
  
APTT     
<28.0 8(18.6%) 0(0%) 
0.580 
 
>28.0 35(81.4%) 7(100%) 
 
  
ASV vials given     
Not given 6(14%) 4(57.1%)   
1-10 7(16.3%) 0(0%)   
11-20 18(41.9%) 2(28.6%) 0.184  
21-30 10(23.3%) 1(14.3%)   
>30 2(4.7%) 0(0%)   
Platelet count     
<1.5 lakh 11(25.6%) 2(28.6%) 
0.307 
 
>1.5 lakh 32(74.4%) 5(71.4%) 
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Figure 24: Association of Lab parameters according to outcome 
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Comparison of lab parameters in good and poor outcome 
group shows significant p-value for PT-INR (0.020).  
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Table 26: Stage of AKI of patients studied 
 
Stages of AKI Number of patients % 
   
Stage I 42 84.0 
   
Stage II 2 4.0 
   
Stage III 6 12.0 
   
Total 50 100.0 
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Figure 25: Stage of AKI of patients studied 
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Forty-two patients (84%) were in Stage I AKI, 2 (4%) were in 
Stage II and 6 (12%) patients were in Stage III AKI. 
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DISCUSSION 
 In the present study, 50 cases were selected on the basis of 
simple random sampling method from the OPD and medical wards 
Government Rajaji Hospital, who had developed snake bite induced 
AKI. 
1. Study Period 
June 2014 to October 2014 
2. Age Distribution 
Studies Mean Age (Years) SD 
Present Study 43.8 12.63 
  
The Mean age of present study population was 43+12.63 years. 
3. Sex Distribution 
Studies Male Female 
Present Study 62% 38% 
 
 In the present study, males account for 62%. 
4. Lapse of time in hours 
Studies No.of Patients Percentage 
Present Study 14 28% 
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5. Symptoms  
Symptoms Present Study 
Reduced urine output 60% 
Bleeding from bite site 32% 
Bleeding from gums 18% 
Signs of inflammation 98% 
 
 Signs of inflammation in the present study were 98%. 
6. Coagulation profile except platelet count 
Studies No.of Patients Percentage 
Present Study 26 52% 
 
 Abnormal coagulation profile was observed in 52% patients. 
7. Platelet count 
Studies No.of Patients Percentage 
Present Study 13 26% 
 
8. Whole Blood Clotting Time (WBCT) 
Studies No.of Patients Percentage 
Present Study 35 70% 
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9. Significant variables 
Variables  Present Study 
Percentage P-Value 
Signs of inflammations 98% 1.00 
Lapse of time >12 hours 28% 0.005 
Mean Cr in mg/dl 3.02 <0.001 
Mean B. Urea in mg/dl 81.92 <0.001 
 
 Clinical variables like signs of inflammation, lapse of time of 
<12 hours in presenting to the hospital, mean serum creatinine and 
mean blood urea elevations with significant p-value. 
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SUMMARY 
This study is a descriptive study of 50 randomly selected 
patients with snake bite induced AKI. These patients were admitted 
to Government Rajaji Hospital, Madurai from June 2014 to October 
2014. 
In our study, mean age of patients studied was 43.8±12.63 
years. Male to female ratio was 1.63:1 with male preponderance. The 
mean interval between snakebite and presentation to KR-Hospital 
was 15.37 hours. All snake bites were inflicted to lower limbs and 
48% of snake bites were due to Viper as identified by patients. 
Ninety-eight per cent of patients presented with local signs of 
inflammation indicating the vasculotoxic nature of envenomation. 
Fifty-two per cent of patients presented with coagulation abnormality 
and 60% with decreased urine output which were associated with 
increase severity of AKI and need for haemodialysis in 12% (6) of 
patients. 
Only 26% of patients presented with thrombocytopenia which 
was not associated with the severity of AKI. 
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                                        CONCLUSION 
From our study we conclude that  
 Common manifestations of poisonous snake bite include 
cellulitis, abnormal coagulation profile and decreased urine 
output.  
 Overall mortality due to snake bite induced AKI is 6%.  
 Lapse of time in presenting to the hospital and abnormal 
coagulation profile are the predictors of poor outcome in snake 
bite induced acute kidney injury.  
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PROFORMA 
 
 
 
Name :
 :
Age /sex: date of admission : 
 
Occupation : 
 
Address : 
 
A. Presenting complaints  
 
B. History of presenting complaint  
 
Lapse of time after the snake bite: 
 
Type of alternative treatment before coming to hospital: Tourniquet 
application: 
 
Identification of the snake: Urine output: 
 
Hematuria: 
 
Bleeding from the gums: Drooping of eyelids 
[PTOSIS]: Loss of consciousness: Convulsions: 
 
Difficulty in breathing: Headache: 
 
Vomiting: Bite site: Fang mark: 
Local swelling: 
 
Associated with pain: 
 
Bleeding from the bite site: 
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C. Past history 
 
Hypertension: Yes/No 
 
Diabetes mellitus: Yes/No 
 
Pre-existing renal disease: Yes/No 
 
D. Personal history 
 
Appetite: normal/decreased 
 
Diet: veg/mixed 
 
Sleep: disturbed/normal 
 
Bladder: normal 
 
Decreased: Yes/No 
 
Bowel habits: 
 
Additional habits: smoking 
 
Alcohol consumption 
 
E. Menstrual history 
 
Cycle: duration: 
 
Flow: scanty/moderate/heavy 
 
F. General physical examination 
 
built: well/moderate/poorly 
 
nourishment: well/ moderate/poorly 
 
vitals: blood pressure: mmHg in right upper limb in supine position 
pulse rate: bpm 
regular/irregular 
 
volume: 
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character: vessel wall: 
All the peripheral pulses equally felt/not felt 
Radioradial/radiofemoral delay: Yes/No Respiratory rate: cycles/min 
Temperature: 
 
Pallor: present/not present Icterus: Yes/No Clubbing: 
Yes/No Cyanosis: Yes/No Lymphedenopathy: 
Bleeding from gums: Yes/No Local examination of the bite 
site: site: 
 
skin: 
 
fang mark: 
 
bleeding from the site: local edema: 
 
temperature: raised/ not raised tenderness: present/not  
G. Systemic examination 
 
Cardiovascular system: 
 
Respiratory system: 
 
Per abdomen: 
 
CNS examination: 
 
H. Investigations 
 
1. Complete hemogram:  
 
2. Whole blood clotting time:  
 
3. Bleeding time:  
 
4. Blood urea:  
 
baseline: at 24 hours: 2nd day: 
 
3rd day: 
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5. Serum creatinine: baseline:  
 
at 24 hours: 2nd day: 3rd day:  
 
6. Creatine kinase:  
 
7. Prothrombin time:  
 
8. Partial thromboplastin time:  
 
9. USG abdomen  
 
10. Urine output: 
 
baseline: 
 
at 24 hours: 
 
2nd day: 
 
3rd day: 
 
11.Estimated gfr by mdrd formula:  
 
I. Diagnosis  
 
J. Treatment given  
 
hemodialysis: 
 
need for hemodialysis: Yes/No 
 
number of cycles underwent: 
 
after 1st cycle 2nd 3rd 4th 5th 6th 7th 8th 
B. urea: 
S. creatinine: 
Urine output: 
K. Conclusion and comment  
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KEY TO MASTER CHART 
 
 
 
 
 
APTT   Activated Partial Thromboplastin Time 
ASV   Anti Snake Venom 
Bl. Urea   Blood Urea 
CKD   Chronic Kidney Disease 
eGFR   Estimated glomerular filtration rate 
FFP   Fresh Frozen Plasma 
IVE   Intravenous Fluid 
Sr. Creatinine   Serum Creatinine 
TC   Total count 
WBCT   Whole Blood Clotting Time 
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